Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...
First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...
Morning Overview on MSN
New prostate cancer immunotherapy cuts biomarkers by up to 99% in trial
A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...
First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...
A recent study found that men with low testosterone levels were associated with a 60 percent higher risk that prostate cancer could progress to a more aggressive state over time. Prostate cancer is ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
John Tesh shared an update on his 10-year cancer journey in a new interview, saying he's 'still fighting it.' In 2015, the former 'Entertainment Tonight' co-host revealed that he had been diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results